Compassionate use patients were not based on genetic mutations.
The company is looking to treat Alzheimer's, if it works in moderate to severe it will work in mild to moderate
the Jenni Spencer was not a Apoe4 patient, she was PSEN1, those patients get it even earlier. The fact that it seemed to work in that patient with a genetic mutation exhibits the fact that the company can even treat diseases like fragile x and Rett sydrome which are caused by genetic mutations. So it isn't the genetic mutation that bryostatin treats, it is the synaptic networks, no matter the cause of the damage
Market Data 
Markets 
AI
